Literature DB >> 1638016

Development of iron-chelating agents for clinical use.

G M Brittenham.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1638016

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

1.  Pharmaceutical analysis of the oral iron chelator deferiprone (DMHP,L1).

Authors:  R Lange; W Lameijer; C Slijkhuis; D de Kaste
Journal:  Pharm World Sci       Date:  1996-08

2.  Inhibition of lipid peroxidation by a new family of iron chelators. Comparison with desferrioxamine.

Authors:  S Rachidi; C Coudray; P Baret; G Gelon; J L Pierre; A Favier
Journal:  Biol Trace Elem Res       Date:  1994 Apr-May       Impact factor: 3.738

3.  Deferiprone (L1) induced conformation change of hemoglobin: A fluorescence and CD spectroscopic study.

Authors:  D Chakraborty; M Bhattacharyya
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

4.  Iron chelators as therapeutic agents against Pneumocystis carinii.

Authors:  G A Weinberg
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

5.  Biometals in rare neurodegenerative disorders of childhood.

Authors:  Sarah J Parker; Jari Koistinaho; Anthony R White; Katja M Kanninen
Journal:  Front Aging Neurosci       Date:  2013-03-25       Impact factor: 5.750

Review 6.  A risk-benefit assessment of iron-chelation therapy.

Authors:  J B Porter
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.228

7.  Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolaevulinic acid prodrug.

Authors:  Alison Curnow; Alexis Perry; Mark Wood
Journal:  Photodiagnosis Photodyn Ther       Date:  2018-12-13       Impact factor: 3.631

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.